CEO-then-titled Stinchcomb bought 25,744 shares of CURI at $2.78; stock down -23.2% in 90 days, -58.1% from 52-week high.
Clinton Larry Stinchcomb, who was CEO at the time, purchased 25,744 shares at $2.78 on 2026-05-28, increasing his holdings to 2,971,260 shares. The purchase occurs in a severely distressed context: the stock is currently trading at $2.54, down -23.2% over the prior 90 days and -58.1% from its 52-week high of $6.06. Against this steep decline, his cross-ticker track record shows 4 prior open-market buys with an average 90-day return of +28.4% and a 100.00% win rate, suggesting a pattern of purchasing at inflection points. However, at CURI specifically, his prior trading tells a different story: all 5 prior trades were sales (on 2025-11-24, 2025-11-21, 2025-11-20, 2025-06-16, and 2025-06-13), and 4 of 5 were well-timed at the 90-day mark, with his most recent sales in November showing -16.0% and -30.2% 90-day declines—evidence he exited the position ahead of further deterioration. His current purchase, made after these well-timed exits, enters a company that is unprofitable (net income of $-1,328,000.00 in the latest quarter, full-year negative), though revenue grew +40.1% year-over-year. The reversal from seller to buyer at a depressed price point after demonstrable sell-side prescience warrants investor attention to whether fundamentals have stabilized or whether this signals a different assessment of the company's near-term trajectory.